Merck & Co., Inc. (MRK) — closed signal from October 24, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 22, 2026.
Predicted vs. what happened
What happened
Reached its target in 28 days.
The thesis — published October 24, 2025
Merck looks like a steady grower that can hold up when markets are choppy. Signs of rising interest from buyers line up with a strong 93 percent score from a respected stock model. Forecasts for fast growth in U.S. lipid nanoparticle uses could help over time. In the next 0-3 months, the upside seems modest with smaller pullbacks than many tech stocks. Keep an eye on drug patent expirations and pricing rules.
Primary drivers
- More buyers than usual and improving mood among investors supports price now
- High 93 percent score from a respected stock-picking checklist used by pros
- Expected growth in lipid nanoparticle uses could lift future sales
- Stable cash coming in from key drugs helps steady the business over time
How it played out
MRK: target reached in 28 days
Lyra published MRK at 86.81 on 2025-10-24 with a short-term 12 percent growth expectation. The thesis pointed to stronger buyer interest, improving investor mood, a 93 percent stock-model score, expected growth in lipid nanoparticle uses, and stable cash from key drugs. It also noted patent expirations and pricing rules as risks.
Inside the window, the stock reached the 96.4 target in 28 days. It kept rising to a 112.9 peak on 2026-01-08, a 30.1 percent gain from the published price. It ended the window at 109.18. The thesis played out and then some.
What happened during the window
On 2025-10-30, Merck reported third-quarter results. Coverage said sales reached $17.28 billion and adjusted earnings were $2.58 per share. On 2026-01-09, the Wall Street Journal reported that Merck was in talks to buy Revolution Medicines in a deal valued around $30 billion.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.